Results 41 to 50 of about 4,076 (204)

Positron Emission Computed Tomography Imaging of Synaptic Vesicle Glycoprotein 2A in Alzheimer’s Disease

Frontiers in Aging Neuroscience, 2021
Alzheimer’s disease (AD) is the most common neurodegenerative disorder seen in age-dependent dementia. There is currently no effective treatment for AD, which may be attributed in part to lack of a clear underlying mechanism.
Yanyan Kong, Shibo Zhang, Lin Huang, Chencheng Zhang, Fang Xie, Zhengwei Zhang, Qi Huang, Donglang Jiang, Junpeng Li, Weiyan Zhou, Tao Hua, Bomin Sun, Jiao Wang, Yihui Guan   +13 more
doaj   +1 more source

Feasibility of imaging synaptic density in the human spinal cord using [11C]UCB-J PET

EJNMMI Physics, 2022
Purpose Neuronal damage and synapse loss in the spinal cord (SC) have been implicated in spinal cord injury (SCI) and neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS).
Samantha Rossano, Takuya Toyonaga, Jason Bini, Nabeel Nabulsi, Jim Ropchan, Zhengxin Cai, Yiyun Huang, Richard E. Carson   +7 more
doaj   +1 more source

Table_3_Connectivity Mapping Using a Novel sv2a Loss-of-Function Zebrafish Epilepsy Model as a Powerful Strategy for Anti-epileptic Drug Discovery.xlsx

, 2022
Synaptic vesicle glycoprotein 2A (SV2A) regulates action potential-dependent neurotransmitter release and is commonly known as the primary binding site of an approved anti-epileptic drug, levetiracetam.
Lise Heylen (11561266), Patrice Godard (3476651), Yifan Zhang (119570), Michèle Partoens (12620839), Aleksandra Siekierska (11561278), Rafal M. Kaminski (12620842), Peter A. M. de Witte (11561275), James D. Mills (9418733), Michel Gillard (261248)   +8 more
core   +1 more source

Epilepsy caused by an abnormal alternative splicing with dosage effect of the SV2A gene in a chicken model.

PLoS ONE, 2011
Photosensitive reflex epilepsy is caused by the combination of an individual's enhanced sensitivity with relevant light stimuli, such as stroboscopic lights or video games.
Marine Douaud, Katia Feve, Fabienne Pituello, David Gourichon, Simon Boitard, Eric Leguern, Gérard Coquerelle, Agathe Vieaud, Cesira Batini, Robert Naquet, Alain Vignal, Michèle Tixier-Boichard, Frédérique Pitel   +12 more
doaj   +1 more source

Exploring the interaction of SV2A with racetams using homology modelling, molecular dynamics and site-directed mutagenesis. [PDF]

PLoS ONE, 2015
The putative Major Facilitator Superfamily (MFS) transporter, SV2A, is the target for levetiracetam (LEV), which is a successful anti-epileptic drug. Furthermore, SV2A knock out mice display a severe seizure phenotype and die after a few weeks.
Joanna Lee, Veronique Daniels, Zara A Sands, Florence Lebon, Jiye Shi, Philip C Biggin   +5 more
doaj   +1 more source

A New SV2A Ligand for Epilepsy

Cell, 2016
Since the 1970s, racetams have been in use as cognitive enhancers. Levetiracetam was discovered to have antiseizure activity in animal models and was then found to bind to SV2A in synaptic and endocrine vesicles. Brivaracetam, an analog of levetiracetam, was identified in a medicinal chemistry campaign with the objective of discovering analogs with ...
openaire   +2 more sources

SV2A/B KO neurons are resistant to TeNT.

, 2013
(A) Mouse spinal cord neurons with the following genotypes: WT, SV2B KO [SV2A (+/+) SV2B (−/−)], and SV2A/B KO [SV2A (−/−) SV2B (−/−)], were exposed to HCR/T (50 nM).
Jun Yao (9646), William H. Tepp (226108), Min Dong (123378), Felix L. Yeh (359699), Eric A. Johnson (225183), Guangyun Lin (323901), Edwin R. Chapman (359702)   +6 more
core   +1 more source

Association of Aβ deposition and regional synaptic density in early Alzheimer’s disease: a PET imaging study with [11C]UCB-J

Alzheimer’s Research & Therapy, 2021
Background Attempts to associate amyloid-β (Aβ) pathogenesis with synaptic loss in Alzheimer’s disease (AD) have thus far been limited to small numbers of postmortem studies.
Ryan S. O’Dell, Adam P. Mecca, Ming-Kai Chen, Mika Naganawa, Takuya Toyonaga, Yihuan Lu, Tyler A. Godek, Joanna E. Harris, Hugh H. Bartlett, Emmie R. Banks, Victoria L. Kominek, Wenzhen Zhao, Nabeel B. Nabulsi, Jim Ropchan, Yunpeng Ye, Brent C. Vander Wyk, Yiyun Huang, Amy F. T. Arnsten, Richard E. Carson, Christopher H. van Dyck   +19 more
doaj   +1 more source

Structural Basis of Botulinum Toxin Type F Binding to Glycosylated Human SV2A: In Silico Studies at the Periphery of a Lipid Raft

Biomolecules, 2022
Botulinum neurotoxins are the deadliest microbial neurotoxins in humans, with a lethal dose of 1 ng/kg. Incidentally, these neurotoxins are also widely used for medical and cosmetic purposes.
Fodil Azzaz, Didier Hilaire, Jacques Fantini   +2 more
doaj   +1 more source

Table_1_Connectivity Mapping Using a Novel sv2a Loss-of-Function Zebrafish Epilepsy Model as a Powerful Strategy for Anti-epileptic Drug Discovery.xlsx

, 2022
Synaptic vesicle glycoprotein 2A (SV2A) regulates action potential-dependent neurotransmitter release and is commonly known as the primary binding site of an approved anti-epileptic drug, levetiracetam.
Lise Heylen (11561266), Patrice Godard (3476651), Yifan Zhang (119570), Michèle Partoens (12620839), Aleksandra Siekierska (11561278), Rafal M. Kaminski (12620842), Peter A. M. de Witte (11561275), James D. Mills (9418733), Michel Gillard (261248)   +8 more
core   +1 more source